Advances in Heart Failure - Is It Time to Redefine Patient Selection for Sodium-Glucose Co-transporter 2 Inhibitors?

Published: 09 October 2020

  • Views:

    Views Icon 591

  • Likes:

    Heart Icon 7
  • episode_image
    16m 28s
    Part 4 Q&A Discussion
    Martin R Cowie, Faiez Zannad, Sanjay Kaul
Average (ratings)
No ratings
Your rating

Overview

This educational symposium was originally broadcast as part of the ESC 2020 Digital Congress.

 

The programme focuses on summarising recent data on SGLT2 inhibitors showing reductions in CV risk, HF hospitalisations  and mortality, as well as improved quality-of-life. The expert panel also discuss how these agents should be introduced into clinical practice and contemporary heart failure guidelines for both diabetics and non-diabetics.

This independent medical education symposium was supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company alliance.

Learning Objectives

  • Discuss Current SGLT2 Data and Guideline Recommendations for Utilization in Heart Failure
  • Evaluate Emerging Data on the Treatment of Heart Failure with SGLT2 Inhibitors
  • Understand the Implications of Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors

More from this programme

Part 1

SGLT2s as a Heart Failure Drug – How Did We Get Here?

1 session
SGLT2s as a Heart Failure Drug – How Did We Get Here? Watch now

Part 2

Emerging Data SGLT2 Inhibitors in Heart Failure

1 session
Emerging Data SGLT2 Inhibitors in Heart Failure Watch now

Part 3

Guidelines and Practice Implications

1 session
Guidelines and Practice Implications Watch now

Part 4

Q&A Discussion

1 session
Q&A Discussion Watch now

Part 5

Follow-up Peer-to Peer Discussion

1 session
Follow-up Peer-to Peer Discussion Watch now

Faculty Biographies

Faiez Zannad

Faiez Zannad

Professor of Therapeutics and Cardiology, Head of CIC

Prof Faiez Zannad is Professor of Therapeutics & Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU).

Prof Zannad is currently the Chairman of the ESC Working group on Pharmacology and Drug Therapy as well as a Boardmember of the ESC Heart Failure Association. He is Past-President of the French Society of Hypertension. 

Prof Zannad is Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.

View full profile